C4 Therapeutics Inc (NASDAQ: CCCC) is -55.08% lower on its value in year-to-date trading and has touched a low of $1.09 and a high of $7.66 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CCCC stock was last observed hovering at around $2.02 in the last trading session, with the day’s loss setting it -0.03%.
Currently trading at $1.99, the stock is 26.47% and 31.15% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.33 million and changing -1.49% at the moment leaves the stock -38.00% off its SMA200. CCCC registered -44.72% loss for a year compared to 6-month loss of -51.34%. The firm has a 50-day simple moving average (SMA 50) of $1.5174 and a 200-day simple moving average (SMA200) of $3.2098.
The stock witnessed a 18.45% gain in the last 1 month and extending the period to 3 months gives it a 65.15%, and is 30.92% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 13.08% over the week and 9.95% over the month.
C4 Therapeutics Inc (CCCC) has around 110 employees, a market worth around $141.30M and $39.78M in sales. Profit margin for the company is -259.60%. Distance from 52-week low is 83.41% and -74.02% from its 52-week high. The company has generated returns on investments over the last 12 months (-40.73%).
The EPS is expected to shrink by -13.82% this year
162.0 institutions hold shares in C4 Therapeutics Inc (CCCC), with institutional investors hold 101.83% of the company’s shares. The shares outstanding are 70.99M, and float is at 54.23M with Short Float at 11.76%. Institutions hold 91.87% of the Float.
The top institutional shareholder in the company is LYNX1 CAPITAL MANAGEMENT LP with over 6.88 million shares valued at $31.79 million. The investor’s holdings represent 9.9993 of the CCCC Shares outstanding. As of 2024-06-30, the second largest holder is RA CAPITAL MANAGEMENT, L.P. with 4.88 million shares valued at $22.54 million to account for 7.0891 of the shares outstanding. The other top investors are WASATCH ADVISORS LP which holds 4.85 million shares representing 7.0442 and valued at over $22.39 million, while BLACKROCK INC. holds 6.6146 of the shares totaling 4.55 million with a market value of $21.03 million.
C4 Therapeutics Inc (CCCC) Insider Activity
The most recent transaction is an insider sale by Boyle Scott N, the company’s Chief Business Officer. SEC filings show that Boyle Scott N sold 669 shares of the company’s common stock on Feb 18 ’25 at a price of $3.15 per share for a total of $2107.0. Following the sale, the insider now owns 0.11 million shares.
C4 Therapeutics Inc disclosed in a document filed with the SEC on Feb 14 ’25 that Boyle Scott N (Chief Business Officer) sold a total of 490 shares of the company’s common stock. The trade occurred on Feb 14 ’25 and was made at $3.15 per share for $1544.0. Following the transaction, the insider now directly holds 0.11 million shares of the CCCC stock.
